Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Milton S. Hershey Medical Center
University of Virginia
Celgene
Memorial Sloan Kettering Cancer Center
University of Iowa
Children's Oncology Group
University of Colorado, Denver
University of Iowa
National Cancer Institute (NCI)
University of Iowa
National Cancer Institute (NCI)
Novartis
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Pfizer
Eli Lilly and Company